All Stories

  1. A Niclosamide Prodrug SSL-0024 with Enhanced Bioavailability Suppresses Hepatocellular Carcinoma via Multi-Pathway Signaling Inhibition

    Article • March 2026, openRxiv

    Renumathy Dhanasekaran

  2. Unraveling the tapestry: Lessons from multi-omics and spatial biology in hepatocellular cancer

    Article • Hepatology, February 2026, Wolters Kluwer Health

    Renumathy Dhanasekaran

  3. Author Correction: Matrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver

    Article • Nature, November 2025, Springer Science + Business Media

    Renumathy Dhanasekaran

  4. Supplementary Figures from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages

    Article • November 2025, American Association for Cancer Research (AACR)

    Renumathy Dhanasekaran

  5. Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages

    Article • November 2025, American Association for Cancer Research (AACR)

    Renumathy Dhanasekaran

  6. The Immune Microenvironment of Transplant Glomerulitis

    Article • Kidney International Reports, September 2025, Elsevier

    Renumathy Dhanasekaran

  7. Redefining cancer care: the case for an onco-gastroenterology subspecialty

    Article • Nature Reviews Gastroenterology & Hepatology, May 2025, Springer Science + Business Media

    Renumathy Dhanasekaran

  8. Practical approach to diagnose and manage benign liver masses

    Article • Hepatology Communications, October 2024, Wolters Kluwer Health

    Renumathy Dhanasekaran

  9. Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease

    Article • Nature Cancer, September 2024, Springer Science + Business Media

    Renumathy Dhanasekaran

  10. Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma

    Article • Journal of Hepatology, March 2024, Elsevier

    Renumathy Dhanasekaran

  11. Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma

    Article • Nature Communications, February 2024, Springer Science + Business Media

    Renumathy Dhanasekaran

  12. Matrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver

    Article • Nature, January 2024, Springer Science + Business Media

    Renumathy Dhanasekaran

  13. Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the “all-comers” protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium

    Article • Arabian archaeology and epigraphy, November 2023, Elsevier

    Renumathy Dhanasekaran

  14. Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making

    Article • Hepatology, June 2023, Wolters Kluwer Health

    Renumathy Dhanasekaran

  15. Data from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages

    Article • March 2023, American Association for Cancer Research (AACR)

    Renumathy Dhanasekaran

  16. Data from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages

    Article • March 2023, American Association for Cancer Research (AACR)

    Renumathy Dhanasekaran

  17. Supplementary Figures from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages

    Article • March 2023, American Association for Cancer Research (AACR)

    Renumathy Dhanasekaran

  18. Supplementary Figures from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages

    Article • March 2023, American Association for Cancer Research (AACR)

    Renumathy Dhanasekaran

  19. Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages

    Article • March 2023, American Association for Cancer Research (AACR)

    Renumathy Dhanasekaran

  20. Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages

    Article • March 2023, American Association for Cancer Research (AACR)

    Renumathy Dhanasekaran

  21. MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint

    Article • Proceedings of the National Academy of Sciences, March 2023, Proceedings of the National Academy of Sciences

    Dr Nicholas M Riley, Renumathy Dhanasekaran

  22. Long-term clinical outcomes of patients with COVID-19 and chronic liver disease: US multicenter COLD study

    Article • Hepatology Communications, January 2023, Wolters Kluwer Health

    Renumathy Dhanasekaran

  23. MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages

    Article • Cancer Research, December 2022, American Association for Cancer Research (AACR)

    Renumathy Dhanasekaran

  24. MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes

    Article • Oncogene, October 2022, Springer Science + Business Media

    Renumathy Dhanasekaran

  25. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

    Article • Journal of Autoimmunity, October 2022, Elsevier

    Renumathy Dhanasekaran

  26. Clinical characteristics and outcomes in those with primary extrahepatic malignancy and malignant ascites

    Article • BMC Gastroenterology, September 2022, Springer Science + Business Media

    Renumathy Dhanasekaran

  27. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy

    Article • Hepatology Communications, August 2022, Wolters Kluwer Health

    Renumathy Dhanasekaran

  28. Treacherous apoptosis—Cancer cells sacrifice themselves at the altar of heterogeneity

    Article • Hepatology, March 2022, Wolters Kluwer Health

    Renumathy Dhanasekaran

  29. Morphological heterogeneity in beta-catenin–mutated hepatocellular carcinomas: implications for tumor molecular classification

    Article • Human Pathology, January 2022, Elsevier

    Renumathy Dhanasekaran

  30. Implications of genetic heterogeneity in hepatocellular cancer

    Article • January 2022, Elsevier

    Renumathy Dhanasekaran

  31. Effects of immunosuppressive drugs on COVID‐19 severity in patients with autoimmune hepatitis

    Article • Liver International, December 2021, Wiley

    Renumathy Dhanasekaran

  32. Erratum for Efe et al. Outcome of COVID‐19 in patients with autoimmune hepatitis: an international multicenter study

    Article • Hepatology, December 2021, Wolters Kluwer Health

    Renumathy Dhanasekaran

  33. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium

    Article • Gastroenterology, November 2021, Elsevier

    Renumathy Dhanasekaran

  34. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge

    Article • World Journal of Hepatology, September 2021, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Renumathy Dhanasekaran

  35. Current and Emerging Tools for Hepatocellular Carcinoma Surveillance

    Article • Hepatology Communications, September 2021, Wolters Kluwer Health

    Renumathy Dhanasekaran

  36. The MYC oncogene — the grand orchestrator of cancer growth and immune evasion

    Article • Nature Reviews Clinical Oncology, September 2021, Springer Science + Business Media

    Renumathy Dhanasekaran

  37. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B

    Article • Viruses, July 2021, MDPI AG

    Renumathy Dhanasekaran

  38. Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study

    Article • Clinical Gastroenterology and Hepatology, July 2021, Elsevier

    Renumathy Dhanasekaran

  39. Outcome of COVID‐19 in Patients With Autoimmune Hepatitis: An International Multicenter Study

    Article • Hepatology, June 2021, Wiley

    Renumathy Dhanasekaran

  40. Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers

    Article • Hepatology, May 2021, Wolters Kluwer Health

    Renumathy Dhanasekaran

  41. Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC)

    Article • Current Treatment Options in Gastroenterology, March 2021, Springer Science + Business Media

    Renumathy Dhanasekaran

  42. Spontaneous Regression of Hepatocellular Carcinoma: When the Immune System Stands Up to Cancer

    Article • Hepatology, March 2021, Wolters Kluwer Health

    Renumathy Dhanasekaran

  43. Socioeconomic Factors Contribute to the Higher Risk of COVID-19 in Racial and Ethnic Minorities With Chronic Liver Diseases

    Article • Gastroenterology, March 2021, Elsevier

    Renumathy Dhanasekaran

  44. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study

    Article • Journal of Hepatology, March 2021, Elsevier

    Renumathy Dhanasekaran

  45. Posttransplant Outcomes in Older Patients With Hepatocellular Carcinoma Are Driven by Non–Hepatocellular Carcinoma Factors

    Article • Liver Transplantation, March 2021, Wolters Kluwer Health

    Renumathy Dhanasekaran

  46. Deciphering Tumor Heterogeneity in Hepatocellular Carcinoma (HCC)—Multi-Omic and Singulomic Approaches

    Article • Seminars in Liver Disease, January 2021, Thieme Publishing Group

    Renumathy Dhanasekaran

  47. Predictors of Outcomes of Patients Referred to a Transplant Center for Urgent Liver Transplantation Evaluation

    Article • Hepatology Communications, December 2020, Wolters Kluwer Health

    Renumathy Dhanasekaran

  48. Liver Injury in Liver Transplant Recipients With Coronavirus Disease 2019 (COVID‐19): U.S. Multicenter Experience

    Article • Hepatology, December 2020, Wolters Kluwer Health

    Renumathy Dhanasekaran

  49. Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post‐transplant Clinical Outcome

    Article • Clinical Transplantation, November 2020, Wiley

    Renumathy Dhanasekaran

  50. Genomic Landscape of HCC

    Article • Current Hepatology Reports, November 2020, Springer Science + Business Media

    Renumathy Dhanasekaran

  51. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study

    Article • The Lancet Gastroenterology & Hepatology, November 2020, Elsevier

    Renumathy Dhanasekaran

  52. MYC ASO Impedes Tumorigenesis and Elicits Oncogene Addiction in Autochthonous Transgenic Mouse Models of HCC and RCC

    Article • Molecular Therapy — Nucleic Acids, September 2020, Elsevier

    Renumathy Dhanasekaran

  53. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry

    Article • Journal of Hepatology, September 2020, Elsevier

    Renumathy Dhanasekaran

  54. Roadmap to resuming care for liver diseases after coronavirus disease‐2019

    Article • Journal of Gastroenterology and Hepatology, July 2020, Wiley

    Dr Keith Siau, Renumathy Dhanasekaran

  55. MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies

    Article • Nature Communications, June 2020, Springer Science + Business Media

    Renumathy Dhanasekaran

  56. One world, one pandemic, many guidelines: management of liver diseases during COVID-19

    Article • Gut, June 2020, BMJ

    Dr Keith Siau, Renumathy Dhanasekaran

  57. The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GLI1-STAT3 transcriptional complex

    Article • Journal of Biological Chemistry, February 2020, Elsevier

    Renumathy Dhanasekaran

  58. MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity

    Article • eLife, January 2020, eLife

    Renumathy Dhanasekaran

  59. MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T- Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling

    Article • Blood, November 2019, American Society of Hematology

    Renumathy Dhanasekaran

  60. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma

    Article • Gastroenterology, November 2019, Elsevier

    Renumathy Dhanasekaran

  61. The Immune Landscape of Cancer

    Article • Immunity, August 2019, Elsevier

    Renumathy Dhanasekaran

  62. A Tale of Two Complications of Obesity: NASH and Hepatocellular Carcinoma

    Article • Hepatology, May 2019, Wiley

    Renumathy Dhanasekaran

  63. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study

    Article • Gastroenterology, May 2019, Elsevier

    Renumathy Dhanasekaran

  64. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy

    Article • Gastroenterology, January 2019, Elsevier

    Renumathy Dhanasekaran

  65. MYC Functions as a Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies

    Article • December 2018, openRxiv

    Renumathy Dhanasekaran

  66. MYC Functions As a Master Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies

    Article • Blood, November 2018, American Society of Hematology

    Renumathy Dhanasekaran

  67. Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma

    Article • Journal for ImmunoTherapy of Cancer, November 2018, Springer Science + Business Media

    Renumathy Dhanasekaran

  68. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily

    Article • Cell Systems, October 2018, Elsevier

    Renumathy Dhanasekaran, Dr Ronald E Warnick

  69. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer

    Article • Cell Reports, October 2018, Elsevier

    Renumathy Dhanasekaran, Dr Ronald E Warnick

  70. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

    Article • Cancer Cell, August 2018, Elsevier

    Renumathy Dhanasekaran

  71. Comprehensive Characterization of Cancer Driver Genes and Mutations

    Article • Cell, August 2018, Elsevier

    Renumathy Dhanasekaran

  72. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

    Article • Cell Reports, June 2018, Elsevier

    Renumathy Dhanasekaran

  73. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

    Article • Cell Reports, April 2018, Elsevier

    Professor Casey Greene, Renumathy Dhanasekaran, Dr Ronald E Warnick

  74. Oncogenic Signaling Pathways in The Cancer Genome Atlas

    Article • Cell, April 2018, Elsevier

    Professor Casey Greene, Renumathy Dhanasekaran, Dr Ronald E Warnick

  75. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers

    Article • Cancer Cell, April 2018, Elsevier

    Renumathy Dhanasekaran, Dr Ronald E Warnick

  76. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples

    Article • Cell, April 2018, Elsevier

    Renumathy Dhanasekaran

  77. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

    Article • Cell, April 2018, Elsevier

    Renumathy Dhanasekaran, Dr Ronald E Warnick

  78. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer

    Article • Cell, April 2018, Elsevier

    Renumathy Dhanasekaran, Dr Ronald E Warnick

  79. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas

    Article • Cancer Cell, April 2018, Elsevier

    Renumathy Dhanasekaran, Dr Ronald E Warnick

  80. Comprehensive Characterization of Cancer Driver Genes and Mutations

    Article • Cell, April 2018, Elsevier

    Renumathy Dhanasekaran

  81. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

    Article • Cell Reports, April 2018, Elsevier

    Renumathy Dhanasekaran, Dr Ronald E Warnick

  82. Genomic and Functional Approaches to Understanding Cancer Aneuploidy

    Article • Cancer Cell, April 2018, Elsevier

    Renumathy Dhanasekaran, Dr Ronald E Warnick

  83. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

    Article • Cell Reports, April 2018, Elsevier

    Renumathy Dhanasekaran, Professor Casey Greene

  84. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

    Article • Cell Reports, April 2018, Elsevier

    Renumathy Dhanasekaran, Dr Ronald E Warnick

  85. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

    Article • Cell Reports, April 2018, Elsevier

    Renumathy Dhanasekaran, Dr Ronald E Warnick

  86. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation

    Article • Cell, April 2018, Elsevier

    Renumathy Dhanasekaran

  87. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

    Article • Cell Reports, April 2018, Elsevier

    Renumathy Dhanasekaran, Dr Ronald E Warnick

  88. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

    Article • Cell Reports, April 2018, Elsevier

    Renumathy Dhanasekaran

  89. Pathogenic Germline Variants in 10,389 Adult Cancers

    Article • Cell, April 2018, Elsevier

    Renumathy Dhanasekaran

  90. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics

    Article • Cell, April 2018, Elsevier

    Renumathy Dhanasekaran

  91. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types

    Article • Cell Reports, April 2018, Elsevier

    Renumathy Dhanasekaran

  92. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

    Article • Cell Reports, April 2018, Elsevier

    Renumathy Dhanasekaran, Dr Ronald E Warnick

  93. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

    Article • Cell Reports, April 2018, Elsevier

    Renumathy Dhanasekaran

  94. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

    Article • Cell Reports, April 2018, Elsevier

    Renumathy Dhanasekaran, Dr Ronald E Warnick

  95. The Immune Landscape of Cancer

    Article • Immunity, April 2018, Elsevier

    Renumathy Dhanasekaran

  96. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer

    Article • Cancer Cell, April 2018, Elsevier

    Renumathy Dhanasekaran

  97. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas

    Article • Cell Systems, March 2018, Elsevier

    Renumathy Dhanasekaran

  98. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines

    Article • Cell Systems, March 2018, Elsevier

    Renumathy Dhanasekaran, Dr Ronald E Warnick

  99. YAP-associated chromosomal instability and cholangiocarcinoma in mice

    Article • Oncotarget, December 2017, Impact Journals, LLC

    Renumathy Dhanasekaran

  100. Ribosomal protein S15a promotes tumor angiogenesis via enhancing Wnt/β-catenin-induced FGF18 expression in hepatocellular carcinoma

    Article • Oncogene, December 2017, Springer Science + Business Media

    Renumathy Dhanasekaran

  101. Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC)

    Article • Oncotarget, November 2017, Impact Journals, LLC

    Renumathy Dhanasekaran

  102. The Liver in Oncology

    Article • Clinics in Liver Disease, November 2017, Elsevier

    Renumathy Dhanasekaran

  103. Abstract 2943: MYC functions as a master switch for natural killer cell-mediated immune surveillance of lymphoid malignancies

    Article • Cancer Research, July 2017, American Association for Cancer Research (AACR)

    Renumathy Dhanasekaran

  104. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma

    Article • Cell, June 2017, Elsevier

    Renumathy Dhanasekaran

  105. Management of Immunosuppression in Liver Transplantation

    Article • Clinics in Liver Disease, May 2017, Elsevier

    Renumathy Dhanasekaran

  106. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy

    Article • American Journal of Clinical Oncology, February 2017, Wolters Kluwer Health

    Renumathy Dhanasekaran

  107. Determinants of the future burden of hepatocellular carcinoma after eradication of hepatitis C virus among cirrhotic patients

    Article • Journal of Hepatology, January 2017, Elsevier

    Renumathy Dhanasekaran

  108. Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma

    Article • Cardiovascular Radiology, November 2016, Springer Science + Business Media

    Renumathy Dhanasekaran

  109. Transcriptional Induction of Periostin by a Sulfatase 2–TGFβ1–SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma

    Article • Cancer Research, November 2016, American Association for Cancer Research (AACR)

    Renumathy Dhanasekaran

  110. Primary Carcinoma of the Liver

    Article • August 2016, Wiley

    Renumathy Dhanasekaran

  111. Erratum to “Clinical implications of basic research in hepatocellular carcinoma” [J Hepatol 2016;64:736–745]

    Article • Journal of Hepatology, June 2016, Elsevier

    Renumathy Dhanasekaran

  112. Pathogenesis of HCC

    Article • F1000Research, May 2016, Faculty of 1000, Ltd.

    Renumathy Dhanasekaran, Lewis Roberts

  113. Sa1362 Identification of Novel Fusions in Gallbladder Cancer by Next Generation Sequencing RNA Analysis - Potential for Targeted Therapy

    Article • Gastroenterology, April 2016, Elsevier

    Renumathy Dhanasekaran

  114. Clinical implications of basic research in hepatocellular carcinoma

    Article • Journal of Hepatology, March 2016, Elsevier

    Renumathy Dhanasekaran

  115. Response to Fibrosis progression in patients treated for hepatitis C recurrence

    Article • Liver International, November 2015, Wiley

    Renumathy Dhanasekaran

  116. Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma

    Article • Current Gastroenterology Reports, August 2015, Springer Science + Business Media

    Renumathy Dhanasekaran

  117. Impact of fibrosis progression on clinical outcome in patients treated for post- transplant hepatitis C recurrence

    Article • Liver International, July 2015, Wiley

    Renumathy Dhanasekaran

  118. Sa1858 Undiagnosed Nonalcoholic Steatohepatitis (NASH) Is Responsible for a Significant Proportion of Cryptogenic Hepatocellular Carcinoma (HCC)

    Article • Gastroenterology, April 2015, Elsevier

    Renumathy Dhanasekaran

  119. 585 Comparative Efficacy of Transarterial Radioembolization (TARE) Versus Chemotherapy or Best Supportive Care for Unresectable Intrahepatic Cholangiocarcinoma (iCCA)

    Article • Gastroenterology, April 2015, Elsevier

    Renumathy Dhanasekaran

  120. Sa1716 Next Generation Sequencing and Pathway Analysis Reveals Frequent Activation of the PI3-K/Akt Pathway in Gallbladder Cancer: Potential for Targeted Therapy

    Article • Gastroenterology, April 2015, Elsevier

    Renumathy Dhanasekaran

  121. Activation of the transforming growth factor-β/SMAD transcriptional pathway underlies a novel tumor-promoting role of sulfatase 1 in hepatocellular carcinoma

    Article • Hepatology, February 2015, Wiley

    Renumathy Dhanasekaran

  122. Liver Transplantation for Hepatocellular Carcinoma

    Article • Current Transplantation Reports, September 2014, Springer Science + Business Media

    Renumathy Dhanasekaran

  123. Vasodilator-stimulated phosphoprotein promotes activation of hepatic stellate cells by regulating Rab11-dependent plasma membrane targeting of transforming growth factor beta receptors

    Article • Hepatology, September 2014, Wiley

    Renumathy Dhanasekaran

  124. 639 Female Gender Associated With Less Aggressive Tumor Phenotype and Better Survival in HCC

    Article • Gastroenterology, May 2014, Elsevier

    Renumathy Dhanasekaran

  125. 770 Sulfatase2 (SULF2) Promotes Angiogenesis in Hepatocellular Carcinoma Partly Through the TGFβ1/Periostin Signaling Pathway

    Article • Gastroenterology, May 2014, Elsevier

    Renumathy Dhanasekaran

  126. P1001 CLINICAL OUTCOMES AFTER RESECTION IN PATIENTS WITH NASH-RELATED HCC

    Article • Journal of Hepatology, April 2014, Elsevier

    Renumathy Dhanasekaran

  127. Challenges of recurrent hepatitis C in the liver transplant patient

    Article • World Journal of Gastroenterology, January 2014, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Renumathy Dhanasekaran

  128. Response to Houlihan et al.

    Article • The American Journal of Gastroenterology, November 2013, Nature

    Renumathy Dhanasekaran

  129. Mo1847 Analysis of Paired Biopsies to Assess Progression of Fibrosis in Patients Treated for Post-Transplant Hepatitis C Recurrence

    Article • Gastroenterology, May 2013, Elsevier

    Renumathy Dhanasekaran

  130. Mo1891 Rate and Predictors of Progression and Mortality in a Large Population Based Cohort of Be

    Article • Gastroenterology, May 2013, Elsevier

    Renumathy Dhanasekaran

  131. Tu1039 Is NASH Related HCC Different From HCC Related to Other Causes

    Article • Gastroenterology, May 2013, Elsevier

    Renumathy Dhanasekaran

  132. Safety and Efficacy of Doxorubicin Drug-eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma

    Article • Journal of Vascular and Interventional Radiology, March 2013, Elsevier

    Renumathy Dhanasekaran

  133. Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma

    Article • Oncology Reports, February 2013, Spandidos Publications

    Renumathy Dhanasekaran

  134. Hepatic Preservation Injury: Severity of Hepatitis C Recurrence and Survival After Liver Transplantation

    Article • Digestive Diseases and Sciences, January 2013, Springer Science + Business Media

    Renumathy Dhanasekaran

  135. Chinese Skullcap in Move Free Arthritis Supplement Causes Drug Induced Liver Injury and Pulmonary Infiltrates

    Article • Case Reports in Hepatology, January 2013, Hindawi Publishing Corporation

    Renumathy Dhanasekaran

  136. Incidentally Discovered HCC (iHCC) in Explant Liver-Histopathologic Features and Clinical Outcome

    Article • Journal of Cancer Therapy, January 2013, Scientific Research Publishing, Inc,

    Renumathy Dhanasekaran

  137. Chemoembolization Combined with RFA for HCC:Survival Benefits and Tumor Treatment Response

    Article • Journal of Cancer Therapy, January 2013, Scientific Research Publishing, Inc,

    Renumathy Dhanasekaran

  138. Influence of transjugular intrahepatic portosystemic shunt in patients awaiting orthotopic liver transplant on post-transplant outcome

    Article • Gastrointestinal Intervention, December 2012, Elsevier

    Renumathy Dhanasekaran

  139. Predictors of early mortality post transjugular intrahepatic portosystemic shunts and the role of hepatic venous pressure gradient

    Article • Gastrointestinal Intervention, December 2012, Elsevier

    Renumathy Dhanasekaran

  140. Liver Test Results Do Not Identify Liver Disease in Adults With α1-Antitrypsin Deficiency

    Article • Clinical Gastroenterology and Hepatology, November 2012, Elsevier

    Renumathy Dhanasekaran

  141. Impact of Transarterial Therapy in Hepatitis C-Related Hepatocellular Carcinoma on Long-term Outcomes After Liver Transplantation

    Article • American Journal of Clinical Oncology, August 2012, Wolters Kluwer Health

    Renumathy Dhanasekaran

  142. Prognostic Value of 18F-Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in Predicting Survival in Patients with Unresectable Metastatic Melanoma to the Liver Undergoing Yttrium-90 Radioembolization

    Article • Journal of Vascular and Interventional Radiology, July 2012, Elsevier

    Renumathy Dhanasekaran

  143. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics

    Article • Hepatic Medicine Evidence and Research, May 2012, Taylor & Francis

    Renumathy Dhanasekaran

  144. Emerging Therapies for Hepatocellular Carcinoma

    Article • January 2012, Springer Science + Business Media

    Renumathy Dhanasekaran

  145. Rare Case of Adult Undifferentiated (Embryonal) Sarcoma of the Liver Treated with Liver Transplantation: Excellent Long-Term Survival

    Article • Case Reports in Hepatology, January 2012, Hindawi Publishing Corporation

    Renumathy Dhanasekaran

  146. Tumoral and angiogenesis factors in hepatocellular carcinoma after locoregional therapy

    Article • Pathology - Research and Practice, January 2012, Elsevier

    Renumathy Dhanasekaran

  147. 537 A SUSTAINED VIRAL RESPONSE DRAMATICALLY IMPROVES SURVIVAL IN PATIENTS WITH HEPATITIS C INFECTION AFTER LIVER TRANSPLANT

    Article • Journal of Hepatology, March 2011, Elsevier

    Renumathy Dhanasekaran

  148. 890 ALT ABNORMALITIES IN ADULTS WITH ALPHA-1 ANTITRYPSIN DEFICIENCY

    Article • Journal of Hepatology, March 2011, Elsevier

    Renumathy Dhanasekaran

  149. The Effectiveness of Locoregional Therapies versus Supportive Care in Maintaining Survival within the Milan Criteria in Patients with Hepatocellular Carcinoma

    Article • Journal of Vascular and Interventional Radiology, August 2010, Elsevier

    Renumathy Dhanasekaran

  150. Long-term survival after locoregional therapy in patients with unresectable hepatocellular carcinoma: Improvements over two decades.

    Article • Journal of Clinical Oncology, May 2010, American Society of Clinical Oncology (ASCO)

    Renumathy Dhanasekaran

  151. Tumoral and angiogenesis factors in hepatocellular carcinoma (HCC) after drug eluting bead (DEB) transarterial chemoembolization (TACE) with doxorubicin.

    Article • Journal of Clinical Oncology, May 2010, American Society of Clinical Oncology (ASCO)

    Renumathy Dhanasekaran

  152. S1920 Influence of Patient Age on Short Term and Long Term Survival After Tips

    Article • Gastroenterology, May 2010, Elsevier

    Renumathy Dhanasekaran

  153. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study

    Article • HPB, April 2010, Elsevier

    Renumathy Dhanasekaran

  154. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC)

    Article • Journal of Surgical Oncology, January 2010, Wiley

    Renumathy Dhanasekaran

  155. Pancrelipase for pancreatic disorders: An update

    Article • Drugs of Today, January 2010, Portico

    Renumathy Dhanasekaran

  156. Transjugular Intrahepatic Portosystemic Shunt for Symptomatic Refractory Hepatic Hydrothorax in Patients With Cirrhosis

    Article • The American Journal of Gastroenterology, November 2009, Nature

    Renumathy Dhanasekaran